Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SHMT1 | P34896 | 5/20 | 0.48 |
| ▸ | SHMT2 | P34897 | 4/20 | 0.48 |
| ▸ | CDC7 | O00311 | 2/20 | 0.45 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.45 |
| ▸ | ALPL | P05186 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | PRKCG | P05129 | 1/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.40 |
| ▸ | IL1R1 | P14778 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.40 |
| ▸ | PRKCH | P24723 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075214 | 0.83 | PTPN11 (0.55) | KDM4EMAPTKMT2ASMN1; SMN2PTPN11 | |
| SCHEMBL2073937 | 0.81 | TRPM8 (0.56) | KDM4EMAPTKMT2ASMN1; SMN2SLC6A3 | |
| SCHEMBL12158178 | 0.77 | CRHR1 (0.44) | KDM4EMAPTKMT2ASMN1; SMN2S1PR4 | |
| SCHEMBL3843833 | 0.76 | KDM4E (0.51) | KDM4EMAPTSHMT1SHMT2CDC7 | |
| SCHEMBL2076554 | 0.75 | TRPM8 (0.64) | KDM4EMAPTCDC7DBF4KMT2A | |
| SCHEMBL18004021 | 0.74 | MAPT (0.55) | KDM4EMAPTSHMT1SHMT2CDC7 | |
| SCHEMBL18003099 | 0.74 | L3MBTL1 (0.58) | KDM4EMAPTSHMT1SHMT2CDC7 | |
| SCHEMBL4368811 | 0.73 | CDC7 (0.51) | KDM4EMAPTCDC7DBF4ALPL | |
| SCHEMBL2072755 | 0.73 | TRPM8 (0.52) | KDM4EMAPTKMT2ASMN1; SMN2PTPN11 | |
| SCHEMBL3437699 | 0.73 | GAA (0.68) | KDM4EMAPTSHMT1SHMT2CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1828207-B1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233919-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | KDM4E 1557/4885MAPT 886/4885SHMT1 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.